Cancer immunotherapies have provided hope to patients with triple-negative breast cancer (TNBC) lung metastasis, an aggressive breast cancer expressing neither the estrogen receptor (ER), the progesterone receptor (PR), nor the human epidermal growth factor receptor 2 (HER2) [1,2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.